Aggregating the Evidence on Antiplatelet drugs: A review of recent clinical trials
Overview
The goal of the educational program is to help practitioners assess the comparative effectiveness and safety of antiplatelet therapy medications; understand the evidence regarding appropriate therapy; weigh the benefits, risks, and value of treatment options; and improve the quality of prescribing and patient care.
This course was developed by the Alosa Foundation.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Use dual antiplatelet therapy (aspirin + a newer antiplatelet agent) rather than aspirin monotherapy for patients with acute coronary syndrome (with or without PCI).
- Use aspirin monotherapy for most patients with a history MI (but not acute MI).
- Use clopidogrel or combined aspirin-dipyridamole for the prevention of recurrent vascular events in most patients with recent stroke.
- Avoid routine aspirin use for primary prevention in low-risk patients (e.g. young patients with no cardiovascular history and without risk factors such as diabetes, hypertension or elevated cholesterol).
Course Fees:
MMS Member Physicians: $30
Nonmember Physicians: $55
Allied Health Professionals: $24
Format: Text & Graphics
CME Credit: 2.5 AMA PRA Category 1 Credits™
